Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : The biotechnology mini portfolio -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (46)	9/27/2006 4:19:44 PM
From: dr.praveen	Read Replies (2) \| Respond to of 93

Did you buy them already? Bad luck in timing for us. Sorry...! Exelixis Announces Proposed Public Offering of Common Stock Wednesday September 27, 4:13 pm ET SOUTH SAN FRANCISCO, Calif., Sept. 27 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL - News) announced today that it is offering to sell, subject to market and other conditions, 9,000,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Exelixis also intends to grant the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock to cover over-allotments, if any. All of the shares in the offering are to be sold by Exelixis. Goldman, Sachs & Co. is acting as the sole book-running manager for the offering. Cowen and Company, LLC is acting as the joint lead manager and Banc of America Securities LLC and Piper Jaffray & Co. are acting as co-managers for the offering.